secwatch / observer
8-K filed February 17, 2026, 6:59 PM ET ticker CYTK CIK 0001061983
regulatory confidence high sentiment positive materiality 0.90

Cytokinetics announces European Commission approval of MYQORZO (aficamten) for obstructive HCM

CYTOKINETICS INC

item 8.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-053049
form_type
8-K
ticker
CYTK
cik
0001061983
company_name
CYTOKINETICS INC
filed_at
2026-02-17T23:59:59+00:00
discovered_at
2026-05-14T18:02:34.484407+00:00
generated_at
2026-05-16T02:19:39.795336+00:00
sec_items
["8.01"]
event_type
regulatory
sentiment
positive
materiality_score
0.9
calibrated_materiality_score
0.9
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-053049
json_url
https://secwatch.observer/filing/0001193125-26-053049.json
markdown_url
https://secwatch.observer/filing/0001193125-26-053049.md
text_url
https://secwatch.observer/filing/0001193125-26-053049.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1061983/000119312526053049/0001193125-26-053049-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1061983/000119312526053049/cytk-20260217.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Comparable filings

OTLK

Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days

Outlook Therapeutics, Inc. June 1, 2026, 9:15 AM ET regulatory Items 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

BBIO

FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026

BridgeBio Pharma, Inc. May 27, 2026, 4:01 PM ET regulatory Items 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

OTLK

FDA grants Outlook Therapeutics appeal; BLA resubmission planned for June 2026

Outlook Therapeutics, Inc. May 26, 2026, 7:15 AM ET regulatory Items 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

RGTI

Rigetti signs LOI for up to $100M CHIPS Act award for quantum R&D; government to receive equity

Rigetti Computing, Inc. May 21, 2026, 7:30 AM ET regulatory Items 3.02, 8.01, 7.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

ONC

BeOne Medicines gets FDA accelerated approval for BEQALZI (sonrotoclax) in R/R MCL

BeOne Medicines Ltd. May 15, 2026, 4:08 PM ET regulatory Items 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

AARD

FDA places full clinical hold on Aardvark's ARD-101 IND; HERO and OLE trials paused

Aardvark Therapeutics, Inc. May 14, 2026, 4:15 PM ET regulatory Items 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

BBIO

BridgeBio submits NDA to FDA for encaleret in ADH1; Phase 3 data shows 76% achieved target calcium levels

BridgeBio Pharma, Inc. May 13, 2026, 4:01 PM ET regulatory Items 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

LESL

Leslie's regains Nasdaq compliance for minimum market value of publicly held shares

Leslie's, Inc. June 1, 2026, 4:28 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-053049
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.